Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized trial of two dose levels of allogeneic adipose-derived mesenchymal stem cells for extensive chronic graft-versus-host disease
2008-004014-27Phase 2Completed
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Feb 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of CSCC_ASC in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoint: Infusion-related toxicity. Started Feb 2010; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2008-004014-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004014-27.